Technical / White Paper
Are there Any Markets left to Emerge?
North America, Western Europe and—to a lesser extent—Australasia once served as prime locations for the majority of research. But these Western markets are approaching saturation, which has led to a lack of naive patients who are available and willing to take part in trials.
Companies have thus turned to new global locations to run trials—an effort made far easier due to the huge improvements that emerging markets have made in investigator and patient identification, as well as regulatory initiatives. Does it matter how far a country has emerged when selecting it as a study location?
